Download PDF
Geburtshilfe Frauenheilkd 2023; 83(10): 1186-1187
DOI: 10.1055/a-2160-6733
DGGG
Mitteilungen aus der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG)

Stellungnahme – Kombinierte Hormonersatztherapie – ein Risiko für demenzielle Erkrankungen?

Biologisch und klinisch nicht plausible Assoziationen
› Further Information
Also available at
    Permissions and Reprints

Eine im Juni 2023 veröffentlichte Studie zum Thema kombinierte Hormonersatztherapie und Demenzrisiko wird in der nachfolgend wiedergegebenen Stellungnahme wegen biologisch und klinisch nicht plausibler Assoziationen kritisch betrachtet.

Publication History

Article published online:
05 October 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Pourhadi N, Mørch LS, Holm EA. et al. Menopausal hormone therapy and dementia: nationwide, nested case-control study. BMJ 2023; 381: e072770
    CrossrefPubMedGoogle Scholar
  • 2 Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F. et al. Use of postmenopausal hormone therapy and risk of Alzheimerʼs disease in Finland: nationwide case-control study. BMJ 2019; 364: l665
    CrossrefPubMedGoogle Scholar
  • 3 Mikkola TS, Savolainen-Peltonen H, Tuomikoski P. et al. Lower Death Risk for Vascular Dementia Than for Alzheimerʼs Disease With Postmenopausal Hormone Therapy Users. JCEM 2017; 102: 870-877
    PubMedGoogle Scholar
  • 4 Shumaker SA, Legault C, Rapp SR. et al. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Womenʼs Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-2662
    CrossrefPubMedGoogle Scholar
  • 5 Espeland MA, Shumaker SA, Leng I. et al. WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013; 173: 1429-1436
    CrossrefPubMedGoogle Scholar
  • 6 Vinogradova Y, Dening T, Hippisley-Cox J. et al. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ 2021; 374: n2182
    CrossrefPubMedGoogle Scholar
  • 7 Matyi JM, Rattinger GB, Schwartz S. et al. Lifetime estrogen exposure and cognition in late life: the Cache County Study. Menopause 2019; 26: 1366-1374
    CrossrefPubMedGoogle Scholar
  • 8 Shao H, Breitner JC, Whitmer RA. et al. Cache County Investigators. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012; 79: 1846-1852
    CrossrefPubMedGoogle Scholar
  • 9 Bagger YZ, Tankó LB, Alexandersen P. et al. PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005; 12: 12-17
    CrossrefPubMedGoogle Scholar
  • 10 Henderson VW. Alzheimerʼs disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 2014; 142: 99-106
    CrossrefPubMedGoogle Scholar
  • 11 Hersi M, Irvine B, Gupta P. et al. Risk factors associated with the onset and progression of Alzheimerʼs disease: A systematic review of the evidence. Neurotoxicology 2017; 61: 143-187
    CrossrefPubMedGoogle Scholar
  • 12 Ilomaki J, Jokanovic N, Tan EC. et al. Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews. Curr Clin Pharmacol 2015; 10: 204-212
    CrossrefPubMedGoogle Scholar
  • 13 Peters R, Peters J, Warner J. et al. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 2008; 37: 505-512
    CrossrefPubMedGoogle Scholar
  • 14 Kantarci K, Manson JE. Menopausal hormone therapy and dementia. BMJ 2023; 381: 1404
    CrossrefPubMedGoogle Scholar